Clinical trials: Schizoaffective Disorders
Agitation, Schizophrenia
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia.
- Conditions
- Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder
- Trial name
- SERENITY I (NCT04268303)
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Schizoaffective Disorder
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine
Atypical antipsychotic medications, such as olanzapine, cause metabolic side effects, including weight gain, extra fat around the middle of the body, high blood sugar, and high cholesterol.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Obesity
- Trial name
- NCT00512070
- Testing
- olanzapine and melatonin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Schizophrenia, Schizoaffective Disorders
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
The goal of this study is to answer the following questions: Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine Whether taking amantadine…
- Trial name
- NCT00401973
- Testing
- olanzapine, amantadine, metformin
- Where
- 15 sites in United States, Brazil and 5 more
- Volunteers
- 199 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Bipolar Disorder
Nonconvulsive Electrotherapy: a Proof-of-concept Trial
This study involves pilot testing of a modified version of a proven treatment for mental illness. The treatment, electroconvulsive therapy (ECT) is used to treat more than 100,000 Americans yearly.
- Conditions
- Depressive Disorder, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT01065597
- Testing
- Nonconvulsive electrotherapy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Maryland, College Park
Schizophrenia, Bipolar Disorder
Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis
The purpose of this study is to better understand mental illness and will test the hypotheses that, while viewing affective stimuli, patient groups will show increased blood oxygenation level dependent (BOLD) signal by fMRI after…
- Conditions
- Schizophrenia, Bipolar Disorder, Healthy, Psychosis
- Trial name
- GABAmech (NCT04004416)
- Testing
- Lorazepam and fMRI
- Where
- United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Schizophrenia, Metabolic Syndrome X
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with…
- Conditions
- Schizophrenia, Metabolic Syndrome X, Insulin Resistance
- Trial name
- NCT00338949
- Testing
- Switch, Control
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia, Bipolar Disorder
Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness
Development of interventions that can effectively target and remediate the cognitive and functional impairment associated with serious mental illness is a treatment priority.
- Conditions
- Schizophrenia, Bipolar Disorder, Schizo Affective Disorder
- Trial name
- NCT03208036
- Testing
- TDCS, Cognitive Remediation, Bridging Group
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
The purpose of this study is to evaluate the tolerability and safety of paliperidone ER (extended-release) in doses between 3 milligrams per day and 12 milligrams per day in the treatment of patients with schizophrenia or…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00535145
- Testing
- Treatment as usual (TAU), Paliperidone ER
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Schizophrenia, Schizo-affective Disorder
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone…
- Trial name
- NCT02658357
- Testing
- Risperidone Implant
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Reducing Internalized Stigma in People With Serious Mental Illness
The purpose of this study is to determine if Ending Self-Stigma (ESS), a 9-session group intervention designed to assist veterans with serious mental illness to develop skills (SMI) to effectively cope with stigma and minimize…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
- Trial name
- ESS (NCT01259427)
- Testing
- Ending Self Stigma (ESS), Health and Wellness Group
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson
Schizoaffective Disorder
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder.
- Trial name
- NCT01193153
- Testing
- paliperidone palmitate
- Where
- 80 sites in United States, Bulgaria and 6 more
- Volunteers
- 667 people
- Sponsor
- Janssen Scientific Affairs, LLC
Schizophrenia, Schizoaffective Disorder
Development of a Mobile System for Self-management of Schizophrenia (SOS)
This 2-arm clinical trial piloted a mobile Self-Management of Schizophrenia (SOS) system that administers interventions targeting persistent symptoms of psychosis, social dysfunction, and medication adherence.
- Trial name
- NCT01969500
- Testing
- Mobile Application, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
Purpose: The purpose of this study is to test new pharmacologic strategies for weight loss in patients with schizophrenia, a population for which no current weight-loss treatments have gained widespread use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Overweight
- Trial name
- MELT (NCT02796144)
- Testing
- Lorcaserin, Metformin
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizo Affective Disorder
Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training
Social impairments are core features of schizophrenia that lead to poor outcome. Social skills and competence improve quality of life and protect against stress-related exacerbation of symptoms, while supporting resilience…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Social Skills
- Trial name
- NCT04005794
- Testing
- social VR (virtual reality) training, Cognitive training (control game)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Schizophrenia, Schizoaffective Disorder
Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
This study will investigate adjunctive pregnenolone for patients with schizophrenia and schizoaffective disorder.
- Trial name
- NCT00728728
- Testing
- Dietary Supplement: Pregnenolone
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- VA Office of Research and Development
Psychotic Disorders, Schizophrenia
A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness
This is a prospective study using a concierge model of customized adherence enhancement and long-acting injectable antipsychotic (CAL-Concierge) in 30 individuals with schizophrenia or schizoaffective disorder at risk for…
- Conditions
- Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Medication Adherence
- Trial name
- CAL-C (NCT02085447)
- Testing
- CAE-L
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia, Schizo Affective Disorder
Telmisartan Pilot Study on Treatment Resistant Schizophrenia
This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective Disorder who have not experienced a significant relief of symptoms from current anti-psychotic medication.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
- Trial name
- NCT03868839
- Testing
- Telmisartan Pill
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Xiaoduo Fan
Schizophrenia, Schizoaffective Disorder
Comparison of E-health vs. In-person Multi-Family Group (MFG)
As specified in the VA Uniform Services Handbook, Family Psycho-Education (FPE) treatment must be available to all Veterans with schizophrenia who could benefit, and their family members.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophrenia and Related Disorders
- Trial name
- NCT02032680
- Testing
- Web-based multi-family psychoeducational treatment, In-persons Multi-Family Group Psycho-Education treatment, Treatment as usual (TAU)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development